Eli Lilly and Company (NYSE:LLY) Stock Price Down 2.2% – Should You Sell?

Eli Lilly and Company (NYSE:LLY – Get Free Report) shares fell 2.2% during mid-day trading on Thursday. The company traded as low as $1,341.46 and last traded at $1,352.1810. 3,064,800 shares were traded during mid-day trading, an increase of 4% from the average daily volume of 2,953,805 shares. The stock had previously closed at $1,382.75.

Trending Headlines about Eli Lilly and Company

Investors following LLY have been watching these headlines:

  • Positive Sentiment: Lilly is broadening its pipeline beyond metabolic drugs: it agreed to acquire Calytrix Bio for up to $1.5 billion and formed an oncology collaboration with Stipple Bio that could be worth up to $5.9 billion. These deals add cancer programs, though they will take time to deliver and require substantial investment. Eli Lilly expands its oncology research platform
  • Positive Sentiment: Analyst and investor coverage includes an RBC Outperform rating and a report highlighting Lilly as one of Ken Fisher’s fastest-growing top positions, supporting the bullish case for continued growth. Eli Lilly in Ken Fisher’s fastest-growing top positions
  • Neutral Sentiment: A report says Lilly is no longer touting dose counts, but the available article details do not explain the change or establish its significance. Investors may look for clarification. Eli Lilly stopped touting dose counts

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Argus lifted their target price on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Truist Financial restated a “buy” rating and issued a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday, October 30th. Scotiabank upped their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a report on Friday, October 30th. China Merchants Securities cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, November 12th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and issued a $1,450.00 price objective on shares of Eli Lilly and Company in a research note on Monday, October 26th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,422.00.

View Our Latest Report on LLY

Eli Lilly and Company Stock Performance

The business’s fifty day moving average price is $1,258.86 and its 200-day moving average price is $1,115.99. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The stock has a market capitalization of $1.27 trillion, a PE ratio of 43.89, a P/E/G ratio of 1.69 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same period in the prior year, the company posted $7.02 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 22.46%.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. This represents a 54.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by insiders.

Institutional Trading of Eli Lilly and Company

Large investors have recently modified their holdings of the business. Bank of America Corp DE purchased a new position in Eli Lilly and Company in the second quarter worth $13,522,666,000. Jupiter Topco LLC bought a new position in Eli Lilly and Company in the second quarter valued at $4,667,180,000. Corient Private Wealth LP purchased a new stake in Eli Lilly and Company during the second quarter valued at about $764,116,000. BlackRock Inc. raised its position in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. Finally, State Street Corp raised its position in Eli Lilly and Company by 1.7% during the third quarter. State Street Corp now owns 36,848,565 shares of the company’s stock valued at $42,636,738,000 after purchasing an additional 632,811 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Further Reading

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.